Taurine Supplementation Reduces Oxidative Stress and Improves Cardiovascular Function in an Iron-Overload Murine Model

Circulation

Volumn 109, Issue 15, 2004, Pages 1877-1885

  Oudit, Gavin Y ^a   Trivieri, Maria G ^a   Khaper, Neelam ^a   Husain, Taneya ^b   Wilson, Greg J ^b   Liu, Peter ^a   Sole, Michael J ^a,c   Backx, Peter H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cardiomyopathy; Glutathione; Hemochromatosis; Stress, oxidative; Taurine

Indexed keywords

GLUTATHIONE; IRON; TAURINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; BLOOD PRESSURE; BRADYCARDIA; CARDIOVASCULAR FUNCTION; DIASTOLE; DIET SUPPLEMENTATION; ENZYME BLOOD LEVEL; FIBROSING ALVEOLITIS; HEART MUSCLE; HEART MUSCLE INJURY; HEART RATE; HYPOTENSION; IRON OVERLOAD; LIPID PEROXIDATION; MALE; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLE; TISSUE SECTION;

ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; GLUTATHIONE; HEART DISEASES; HEMODYNAMIC PROCESSES; HEMOSIDEROSIS; MALE; MICE; MYOCARDIUM; OXIDATIVE STRESS; TAURINE;

EID: 1942534543     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000124229.40424.80     Document Type: Article

References (64)

1. Weatherall DJ, Clegg JB. Thalassemia: a global public health problem. Nat Med. 1996;2:847-849.
2. Barton JC, Bertoli LF. Hemochromatosis: the genetic disorder of the twenty-first century. Nat Med. 1996;2:394-395.
3. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.
4. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341: 1986-1995.
5. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38:30-36.
6. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51:209-221.
7. Jensen CE, Tuck SM, Old J, et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol. 1997;59: 76-81.
8. Muhlestein JB. Cardiac abnormalities in hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics. Pathophysiology. Diagnosis, and Treatment. Cambridge, UK: Cambridge University Press; 2000:297-310.
9. Strohmeyer G, Niederau C. Diabetes mellitus and hemochromatosis. In: Barton JC, Edwards CQ, eds. Hemochromatosis: Genetics, Pathophysiology, Diagnosis, and Treatment. Cambridge, UK: Cambridge University Press; 2000:268-277.
10. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther. 1994;8:101-110.
11. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331:574-578.
12. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
13. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110: 1107-1119.
14. Fine JS. Iron poisoning. Curr Probl Pediatr. 2000;30:71-90.
15. Tenenbein M, Kopelow ML, deSa DJ. Myocardial failure and shock in iron poisoning. Hum Toxicol. 1988;7:281-284.
16. Hershko C, Link G, Pinson A. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and alpha-tocopherol in iron-loaded rat myocardial cell cultures. J Lab Clin Med. 1987;110:355-361.
17. Lesnefsky EJ, Allen KG, Carrea FP, et al. Iron-catalyzed reactions cause lipid peroxidation in the intact heart. J Mol Cell Cardiol. 1992;24: 1031-1038.
18. Kadiiska MB, Burkitt MJ, Xiang QH, et al. Iron supplementation generates hydroxyl radical in vivo: an ESR spin-trapping investigation. J Clin Invest. 1995;96:1653-1657.
19. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201.
20. 2 injury in adult cardiomyocytes. Cardiovasc Res. 2000;47:529-536.
21. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-1194.
22. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72: 101-163.
23. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care. 2000;3:417-424.
24. Takihara K, Azuma J, Awata N, et al. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J. 1986;112: 1278-1284.
25. Pion PD, Kittleson MD, Rogers QR, et al. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science. 1987;237:764-768.
26. Moise NS, Pacioretty LM, Kallfelz FA, et al. Dietary taurine deficiency and dilated cardiomyopathy in the fox. Am Heart J. 1991;1121:541-547.
27. Schaffer S, Solododushko V, Azuma J. Taurine-deficient cardiomyopathy: role of phospholipids, calcium and osmotic stress. In: Della Corte L, Huxtable RJ, Sgaragli, G, et al, eds. Taurine 4. Taurine and Excitable Tissues (Advances in Experimental Medicine and Biology, vol 483). New York. NY: Kluwer Academic/Plenum Publishers; 2000:57-69.
28. Alroy J, Rush JE, Freeman L, et al. Inherited infantile dilated cardiomyopathy in dogs: genetic, clinical, biochemical, and morphologic findings. Am J Med Genet. 2000;95:57-66.
29. Satoh H. Electrophysiological and electropharmacological actions of taurine on cardiac cells. In: Della Corte L, Huxtable RJ, Sgaragli, G, et al, eds. Taurine 2. Basic and Clinical Aspects (Advances in Experimental Medicine and Biology, vol 403). New York. NY: Plenum Press; 1996: 285-296.
30. Holloway C, Kotsanas G, Wendt I. Acute effects of taurine on intracellular calcium in normal and diabetic cardiac myocytes. Pflugers Arch. 1999;438:384-391.
31. 2+]-dependent actions of taurine in spontaneously beating rabbit sino-atrial nodal cells. Eur J Pharmacol. 2001;424:19-25.
32. Biasetti M, Dawson R. Effects of sulfur containing amino acids on iron and nitric oxide stimulated catecholamine oxidation. Amino Acids. 2002; 22:351-368.
33. Keith ME, Ball A, Jeejeebhoy KN, et al. Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol. 2001;17: 449-458.
34. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation. 1997;96:2414-2420.
35. Schmidt AG, Gerst M, Zhai J, et al. Evaluation of left ventricular diastolic function from spectral and color M-mode Doppler in genetically altered mice. J Am Soc Echocardiogr. 2002;15:1065-1073.
36. Kremastinos DT, Tsiapras DP, Tsetsos GA, et al. Left ventricular diastolic Doppler characteristics in β-thalassemia major. Circulation. 1993; 88:1127-1135.
37. Ball AM, Sole MJ. Oxidative stress and the pathogenesis of heart failure. Cardiol Clin. 1998;16:665-675.
38. Crichton RR, Wilmet S, Legssyer R, et al. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem. 2002;91:9-18.
39. Sevier CS, Kaiser CA. Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol. 2002;3:836-847.
40. Woo HA, Chae HZ, Hwang SC, et al. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science. 2003; 300:653-656.
41. Link G, Konijn AM, Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med. 1999;133:179-188.
42. Bhatnagar A. Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ Res. 1995;76:293-304.
43. Folden DV, Gupta A, Sharma AC, et al. Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism. Br J Pharmacol. 2003;139: 1310-1316.
44. Artman M, Olson RD, Boucek RJ Jr, et al. Depression of contractility in isolated rabbit myocardium following exposure to iron: role of free radicals. Toxicol Appl Pharmacol. 1984;72:324-332.
45. Bartfay WJ, Hou D, Brittenham GM, et al. The synergistic effects of vitamin E and selenium in iron-overloaded mouse hearts. Can J Cardiol. 1998;14:937-941.
46. Young IS, Trouton TG, Torney JJ, et al. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med. 1994;16:393-397.
47. Livrea MA, Tesoriere L, Pintaudi AM, et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood. 1996;88:3608-3614.
48. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
49. Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science. 2001;292: 2083-2086.
50. Nakaya H, Tohse N, Kanno M. Electrophysiological derangements induced by lipid peroxidation in cardiac tissue. Am J Physiol. 1987;253: H1089-H1097.
51. Schwartz KA, Li Z, Schwartz DE, et al. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol. 2002;93:746-751.
52. Eley DW, Lake N, ter Keurs HE. Taurine depletion and excitation-contraction coupling in rat myocardium. Circ Res. 1994;74:1210-1219.
53. Dawson R Jr. Tang E, Shih D, et al. Taurine inhibition of iron-stimulated catecholamine oxidation. Adv Exp Med Biol. 1998;442:155-162.
54. Eppler B, Dawson R. Cytoprotective role of taurine in a renal epithelial cell culture model. Biochem Pharmacol. 2002;63:1051-1060.
55. Wu QD, Wang JH, Fennessy F, et al. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol. 1999; 277:C1229-C1238.
56. Heller-Stilb B, van Roeyen C, Rascher K, et al. Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J. 2002;231:16.
57. Golubnitschaja O, Moenkemann H, Kim K, et al. DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem Pharmacol. 2003;66: 511-517.
58. Forgione MA, Cap A, Liao R, et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002;106:1154-1158.
59. Li S, Li X, Rozanski GJ. Regulation of glutathione in cardiac myocytes. J Mol Cell Cardiol. 2003;35:1145-1152.
60. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett. 2003;226:195-202.
61. Suzuki T, Wada T, Saigo K, et al. Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. EMBO J. 2002;21:6581-6589.
62. Fennessy FM, Moneley DS, Wang JH, et al. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation. 2003;107:410-415.
63. 2+ channel modifiers: possible implications in iron overload. Circ Res. 1999;84:1302-1309.
64. Templeton DM, Liu Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim Biophys Acta. 2003;1619:113-124.